Mersana Therapeutics' IPO

Mersana Therapeutics raised a round of funding on June 28, 2017. Investors include Public.

Mersana Therapeutics (NASDAQ: MRSN) is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patient…

Articles about Mersana Therapeutics' IPO: